The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review

Conclusion Bevacizumab possess less documented adverse effects when compared to other chemotherapeutic agents. The manifestation and severity of adverse effects reported varied according to the chemotherapeutic agent(s) that were used with bevacizumab in combination therapy. Overall, bevacizumab effectively improved the survival rate in patients with several gynaecological cancers.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research